Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: AIO-Studien-gGmbH
Woman and Man Max 99 years
AIO-Studien-gGmbH
Update Il y a 4 ans
Prospective Randomized Multicenter Phase II Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer Prospektive, randomisierte Phase-II Studie zur intensivierten neoadjuvanten Chemotherapie des lokal fortgeschrittenen Pankreaskarzinoms
To compare the effect of intensified neoadjuvant chemotherapy on conversion rate to resetcability in LAPC. Vergleich der Wirkung intensivierter neoadjuvanter Chemotherapie auf die Konversionsrat...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
AIO-Studien-gGmbH
Update Il y a 5 ans
Étude TITAN-RCC : étude de phase 2 visant à évaluer l’efficacité du nivolumab chez des patients ayant un carcinome des cellules rénales avancé ou métastatique.
Le carcinome des cellules rénales est le type le plus fréquent de cancer du rein. Il peut prendre naissance à partir d’une cellule de différentes parties du rein et avec le temps il peut s’étendre aux...
Country
France
organs
Rein
Specialty
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
AIO-Studien-gGmbH
Update Il y a 4 ans
Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer. Avelumab und Cetuximab in Kombination mit FOLFOX bei Patienten mit unbehandeltem metastasiertem kolorektalem Karzinom
The primary clinical objective is to determine the efficacy of a standard 1st line regimen (FOLFOX and cetuximab) in patients with RAS/BRAF wildtype, MSI or MSS MCRC with avelumab in terms of progress...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AIO-Studien-gGmbH
Update Il y a 4 ans
A clinical trial of a Tailored ImmunoTherapy Approach with Nivolumab in subjects with metastatic or advanced Transitional Cell Carcinoma Eine Studie zur Untersuchung eines abgestuften immuntherapeutischen Ansatzes in Patienten mit einer fortgeschrittenem oder metastasiertem Urothelkrebserkrankung
The primary objective will be measured by the primary endpoint of ORR (based on investigator assessments). The ORR is based on investigator assessment using RECIST 1.1 of the TITAN-TCC regimen in untr...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
AIO-Studien-gGmbH
Update Il y a 4 ans
Vinorelbine In Combination with the mTOR Inhibitor Everolimus vs Vinorelbine monotherapy in Advanced breast cancer
The primary study goal is the evaluation of Progression-free survival (PFS)
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AIO-Studien-gGmbH
Update Il y a 4 ans
A Phase II Study of Cabazitaxel for Patients with Breast or Lung Cancer and Recurrent or Progressive Brain Metastases (CaBaMet) Phase II Studie zur Behandlung mit Cabazitaxel von Patienten mit rezidivierten oder progredienten Hirnmetastasen eines Mammakarzinoms oder Lungenkarzinoms (CaBaMet)
Objective tumor response of brain metastases (BM)
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AIO-Studien-gGmbH
Update Il y a 4 ans
Induction Treatment with nab-Paclitaxel/Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer Followed by Either Alternating Application of Gemcitabine Monotherapy and nab-Paclitaxel/Gemcitabine or Continuing Application of nab-Paclitaxel/Gemcitabine: A Randomized Phase II Study Induktionstherapie mit nab-Paclitaxel/Gemcitabin in der Erstlinienbehandlung des metastasierten Pankreaskarzinoms gefolgt von entweder alternierender Verabreichung von Gemcitabin Monotherapie und nab-Paclitaxel/Gemcitabin oder fortlaufender Verabreichung von nab-Paclitaxel/Gemcitabin: Eine randomisierte Phase II Studie
To estimate the treatment effect of alternating treatment cycles of gemcitabine monotherapy followed by nab-paclitaxel/gemcitabine relative to standard continuing nab-paclitaxel/gemcitabine treatment ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AIO-Studien-gGmbH
Update Il y a 4 ans
Combination chemotherapy mFOLFOX6 versus combination chemotherapy and Aflibercept in patients with locally advanced rectal cancer staged T3 in MRI Kombinationschemotherapie mFOLFOX6 vs. Kombinationschemotherapie mFOLFOX6 + Aflibercept als neoadjuvante Behandlung von Patienten mit wanddurchsetzendem Rektumkarzinom (Stadium T3, im MRT bestimmt): eine randomisierte Phase II- Studie
To investigate the pathological tumor response based on central pathologic review of the mFOLFOX6/aflibercept combination as compared to mFOLFOX6 alone in patients with locally advanced rectal cancer ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AIO-Studien-gGmbH
Update Il y a 4 ans
Comparison of two preemptive treatment strategies of panitumumab mediated skin toxicity and assessment of quality of life in patients with Ras-wildtype colorectal cancer
Percentage of patients developing no skin toxicity ≥ grade 2 at any time during their first 8-weeks of treatment with panitumumab
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AIO-Studien-gGmbH
Update Il y a 4 ans
Randomized Phase II study for evaluation of efficacy and safety of maintenance treatment with 5-FU/FA plus panitumumab vs. 5-FU/FA alone after prior induction treatment with mFOLFOX6 plus panitumumab and re-induction with mFOLFOX6 plus panitumumab in case of progression for first-line treatment of patients with metastatic colorectal cancer Randomisierte Phase-II-Studie über Induktionsbehandlung mit mFOLFOX6 plus Panitumumab gefolgt von Erhaltungsbehandlung mit 5-FU/FA plus Panitumumab versus 5-FU/FA allein und Re-Induktion mit mFOLFOX plus Panitumumab im Falle des Progresses für die Erstlinienbehandlung von Patienten mit metstasiertem Kolorektalkarzinom
To assess the efficacy of panitumumab plus 5-FU/FA as maintenance after an induction treatment of 12 weeks with mFOLFOX6 plus panitumumab in the first-line treatment of KRAS wild type metastatic color...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
Next